Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $24 from $22 and keeps a Buy rating on the shares. The firm is adjusting its model after the company’s Q3 results and FY24 guidance, the analyst tells investors in a research note. Truist is raising its FY24 EBITDA view on Guardian Pharmacy to $87M from $85M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRDN:
- Guardian Pharmacy Services Reports Strong Revenue Growth
- Guardian Pharmacy sees FY24 revenue $1.205B-$1.215B, consensus $1.19B
- Guardian Pharmacy reports Q3 adjusted EBITDA $23.0M, up 20% y/y
- Guardian Pharmacy initiated with a Buy at Truist
- Opening Day: Self-driving startup Pony.ai files for U.S. IPO